MedPath

BAYER AG

BAYER AG logo
🇩🇪Germany
Ownership
Public
Established
1863-08-01
Employees
99.7K
Market Cap
$30.1B
Website
http://www.bayer.com
Clinical Trials
Related News

BAY14-2222 Continuous Infusion in Surgeries

Phase 3
Completed
Conditions
Hemophilia
Interventions
First Posted Date
2008-02-01
Last Posted Date
2010-04-13
Lead Sponsor
Bayer
Target Recruit Count
15
Registration Number
NCT00606060

Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)

Phase 3
Completed
Conditions
Carcinoma, Renal Cell
Interventions
First Posted Date
2008-01-04
Last Posted Date
2014-04-16
Lead Sponsor
Bayer
Target Recruit Count
39
Registration Number
NCT00586105

Long-term Extension From RCC Phase II (11515)

Phase 2
Completed
Conditions
Carcinoma, Renal Cell
Interventions
First Posted Date
2008-01-04
Last Posted Date
2013-12-13
Lead Sponsor
Bayer
Target Recruit Count
95
Registration Number
NCT00586495

BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)

Phase 4
Completed
Conditions
Hematologic Disease
Hemophilia A
Interventions
First Posted Date
2008-01-04
Last Posted Date
2014-11-02
Lead Sponsor
Bayer
Target Recruit Count
20
Registration Number
NCT00586521

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

First Posted Date
2007-12-12
Last Posted Date
2016-09-15
Lead Sponsor
Bayer
Target Recruit Count
8101
Registration Number
NCT00571649
Locations
🇦🇷

Sanatorio Mitre, Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

🇨🇦

CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada

🇨🇦

Hotel Dieu-Grace Hospital, Windsor, Ontario, Canada

and more 10 locations

SH T00186 in the Treatment of Primary Dysmenorrhea

Phase 3
Completed
Conditions
Primary Dysmenorrhea
Interventions
Drug: YAZ (SH T00186D)
First Posted Date
2007-12-07
Last Posted Date
2014-10-29
Lead Sponsor
Bayer
Target Recruit Count
223
Registration Number
NCT00569244

Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.

Phase 2
Completed
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2007-12-06
Last Posted Date
2014-10-29
Lead Sponsor
Bayer
Target Recruit Count
28
Registration Number
NCT00568945

A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis

Phase 4
Completed
Conditions
Mild to Moderate Atopic Dermatitis
Interventions
Device: Zarzenda
First Posted Date
2007-12-06
Last Posted Date
2015-02-18
Lead Sponsor
Bayer
Target Recruit Count
80
Registration Number
NCT00568412
Locations
🇩🇪

Klinik und Poliklinik fuer Dermatologie, Universtitaetsklinikum, Bonn, Germany

Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

Phase 3
Completed
Conditions
Contraception
Ovulation Inhibition
Contraceptives, Oral
Interventions
Drug: EE20/DRSP (BAY86-5300)
Drug: EE20/DRSP (YAZ, BAY86-5300)
First Posted Date
2007-12-04
Last Posted Date
2014-03-12
Lead Sponsor
Bayer
Target Recruit Count
1887
Registration Number
NCT00567164

Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido

Phase 2
Completed
Conditions
Libido
Interventions
Drug: Dehydroepiandrosterone, BAY86-5314
Drug: Placebo
First Posted Date
2007-12-03
Last Posted Date
2014-12-02
Lead Sponsor
Bayer
Target Recruit Count
100
Registration Number
NCT00566384
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy